HER2-Targeted ADCs in Solid Tumors

CME

The Lay of the Land: Overview of Biology of HER2 in Genitourinary, Gastrointestinal, and Gynecologic Malignancies

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: April 21, 2025

Expiration: April 20, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following actionable HER2 alterations is most frequently identified across genitourinary, gastrointestinal, and gynecologic cancers?